Extrawell Pharmaceutical Holdings Limited (0858)

Overview

Extrawell Pharmaceutical Holdings Limited is a prominent investment holding company that focuses on the development, manufacture, marketing, distribution, and sale of a wide range of pharmaceutical products primarily in the People's Republic of China and Hong Kong. Established in 1998 and headquartered in Quarry Bay, Hong Kong, the company has carved a niche for itself in the pharmaceutical industry through its innovative products and solutions. Extrawell operates through three main segments: Manufacturing, Trading, and Gene Development, covering a broad spectrum of healthcare needs from immune regulation and wound healing to the management of skin conditions and high blood pressure. With a focus on both the commercial exploitation and development of genome-related technology, Extrawell is also advancing in the field of biotechnology, particularly in the development of an oral insulin product for diabetes treatment that is currently in clinical trials. Its commitment to improving health outcomes through research, development, and the provision of high-quality pharmaceutical products underlines its mission to contribute positively to the global healthcare landscape.

Products and Services

• Transfer Factor Oral Solution:

  An innovative dual immune regulator designed for the treatment of diseases caused by virus infection and weak cellular immune systems. This product highlights Extrawell’s commitment to advancing immune health.

• Wisk:

  A treatment option for II-III degree radio-injury of the skin, normal common burns, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post-operation wound healing. Its multifaceted application in skin and wound care showcases the company's expertise in developing versatile pharmaceutical products.

• ZhouBang:

  A thromboxane synthetase inhibitor aimed at preventing the coagulation of platelets and facilitating the relaxation of blood vessels. This product represents Extrawell’s foray into cardiovascular health, underscoring its dedication to comprehensive healthcare solutions.

• Imported Pharmaceutical Products:

  Extrawell engages in the marketing and distribution of various imported pharmaceutical products, including Skin-Cap, which is used for the treatment of itching, irritation, redness, and scaly skin issues, and Millibar for high blood pressure management. This segment demonstrates the company’s role in providing access to global healthcare solutions.

• Oral Insulin Product (Clinical Trial Stage):

  Currently in clinical trials, this innovative product is aimed at the treatment of diabetes through oral administration, reflecting Extrawell’s commitment to pioneering solutions in diabetes care and management.

• Genome-Related Technology:

  The company is engaged in the commercial exploitation and development of genome-related technology, which includes holding gene invention rights. This signifies Extrawell’s investment in genetic research and its potential to revolutionize personalized medicine and healthcare.